[go: up one dir, main page]

SG11202111131VA - Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations - Google Patents

Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations

Info

Publication number
SG11202111131VA
SG11202111131VA SG11202111131VA SG11202111131VA SG11202111131VA SG 11202111131V A SG11202111131V A SG 11202111131VA SG 11202111131V A SG11202111131V A SG 11202111131VA SG 11202111131V A SG11202111131V A SG 11202111131VA SG 11202111131V A SG11202111131V A SG 11202111131VA
Authority
SG
Singapore
Prior art keywords
amorphous solid
plasma concentrations
enhanced performance
therapeutic plasma
achieving therapeutic
Prior art date
Application number
SG11202111131VA
Inventor
Robert J Garmise
Jaquan Kalani Levons
Jay Poorna Reddy
Kevin J Stefanski
Vrushali M Waknis
Theresa M Ziemba
Ajay Saxena
Srikanth Koravady Sridhar
Gajendra Singh Chowan
Sharmistha Pal
Shabeerali Pattasseri
Roopa Narasimhamurthy
Narayan Swamy Panduranga
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11202111131VA publication Critical patent/SG11202111131VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202111131VA 2019-04-11 2020-04-10 Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations SG11202111131VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832606P 2019-04-11 2019-04-11
PCT/US2020/027677 WO2020210629A1 (en) 2019-04-11 2020-04-10 Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations

Publications (1)

Publication Number Publication Date
SG11202111131VA true SG11202111131VA (en) 2021-11-29

Family

ID=70465560

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111131VA SG11202111131VA (en) 2019-04-11 2020-04-10 Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations

Country Status (17)

Country Link
EP (1) EP3953355A1 (en)
JP (2) JP2022526656A (en)
KR (1) KR20210151183A (en)
CN (1) CN113924300A (en)
AR (1) AR118650A1 (en)
AU (1) AU2020271103A1 (en)
BR (1) BR112021020257A2 (en)
CA (1) CA3132530A1 (en)
CL (1) CL2021002627A1 (en)
CO (1) CO2021015054A2 (en)
EA (1) EA202192753A1 (en)
IL (1) IL287103A (en)
MX (2) MX2021012288A (en)
PE (1) PE20212367A1 (en)
SG (1) SG11202111131VA (en)
TW (1) TW202104228A (en)
WO (1) WO2020210629A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3212644A1 (en) * 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
JP2024534427A (en) 2021-09-17 2024-09-20 ブリストル－マイヤーズ スクイブ カンパニー Milbexian for preventing and treating thromboembolic disorders
UY40381A (en) 2022-08-01 2024-01-31 Janssen Pharmaceutica Nv USE OF MILVEXIAN FOR THE TREATMENT OR PREVENTION OF ISCHEMIC STROKE
WO2024167899A1 (en) 2023-02-06 2024-08-15 Bristol-Myers Squibb Company Milvexian pharmaceutical compositions
WO2025099743A1 (en) * 2023-11-07 2025-05-15 Dr. Reddy’S Laboratories Limited Process for preparation of milvexian and solid-state forms thereof
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof
WO2025220042A1 (en) * 2024-04-18 2025-10-23 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising asundexian and use thereof
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83812B (en) 1985-11-27 1988-03-15 Syntex Inc Process for preparing amorphous benzimidazole derivatives
PT901786E (en) * 1997-08-11 2007-08-07 Pfizer Prod Inc Solid pharmaceutical dispersions with enhanced bioavailability
WO2010102245A1 (en) 2009-03-05 2010-09-10 Upsher-Smith Laboratories, Inc. Solid dispersion comprising resveratrol
UY40230A (en) * 2014-01-31 2023-08-15 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Macrocycles with heterocyclic P2' groups as inhibitors of factor XIa and pharmaceutical compositions comprising them
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (en) * 2014-10-01 2018-10-20

Also Published As

Publication number Publication date
CA3132530A1 (en) 2020-10-15
TW202104228A (en) 2021-02-01
WO2020210629A1 (en) 2020-10-15
CN113924300A (en) 2022-01-11
IL287103A (en) 2021-12-01
JP2025131625A (en) 2025-09-09
CO2021015054A2 (en) 2021-11-19
EP3953355A1 (en) 2022-02-16
BR112021020257A2 (en) 2021-12-07
US20220144835A1 (en) 2022-05-12
MX2021012288A (en) 2021-11-12
JP2022526656A (en) 2022-05-25
PE20212367A1 (en) 2021-12-21
AR118650A1 (en) 2021-10-20
MX2025011559A (en) 2025-11-03
EA202192753A1 (en) 2022-01-11
KR20210151183A (en) 2021-12-13
AU2020271103A1 (en) 2021-12-02
CL2021002627A1 (en) 2022-05-06

Similar Documents

Publication Publication Date Title
IL287103A (en) Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations
EP4149460B8 (en) Therapeutic solid dosage forms
GB2587486B (en) Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof
IL323369A (en) Topical formulations for treatment of peripheral neuropathies
PH12013501574A1 (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
PH12013501591A1 (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
IN2013MU01696A (en)
EP3860621A4 (en) Iron formulations for topical administration and methods of treatment of iron deficiency
EP4284272A4 (en) Compositions and methods for sustained treatment of pain
IL291543A (en) Therapeutic formulations and uses thereof
IL277913A (en) Topical formulations comprising strontium and methylsulfonylmethane (msm) and niethods of treatment
IL289236A (en) Compositions and methods for treatment of fungal infections
EP3694517A4 (en) Compositions and methods for treatment of fibrosis
EP4138852A4 (en) Compositions and methods for the treatment of pain
EP4164619A4 (en) Treatment methods and formulations
HK40068978A (en) Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations
EP4017873A4 (en) Compositions and methods for the treatment of pathological pain and itch
EP3893847A4 (en) Stable formulations of anesthetics and associated dosage forms
EP4072549A4 (en) Therapeutic compositions and methods for prevention and treatment of diastolic dysfunction
EP3976115A4 (en) Compositions and methods for treatment of hemochromatosis
GB202101161D0 (en) Formulations for the treatment of tendinopathies
HK40112773A (en) Therapeutic formulations and uses thereof
HK40089059A (en) Compositions and methods for the treatment of tdp-43 proteinopathies
GB202001137D0 (en) Formulations for the treatment of tendinopathies
HK40065186A (en) Therapeutic agents and methods of treatment